The Poseidon study was a phase I/II study in second-line KRAS mild-type metastatic colorectal cancer (mCRC) that did not meet its endpoint of progression-free survival, but did suggest a subgroup of patients with high alpha v beta 6 integrin expression who would benefit from abituzumab. In this interview, Dr Rita Laeufle tells us about the retrospective analysis of the Poseidon study, whereby patients with left-sided KRAS wild-type mCRC and high expression of alpha v beta 6 showed improved overall survival and progression-free survival. Dr Laeufle explains how future research will start to focus on first-line therapy and how patients with other types of colon cancer can benefit from these results.
1. What was the background and rationale behind the retrospective explorative analysis of the Poseidon study? (0:11)
2. What were the key findings from the analysis? (2:49)
3. What are the next steps in this area of research over the coming years? (3:27)
4. How do you anticipate these findings will impact clinical practice in the future? (4:33)
Speaker disclosures: Rita Laeufle has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Colorectal Cancer
Benjamin Weingberg, ASCO 2022: Highlights of ASCO in colorectal cancer, dostarlimab and the DYNAMIC study
Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with […]
Benjamin Weingberg, ASCO 2022: Highlights of ASCO in colorectal cancer, the PARADIGM study
PARADIGM is the first prospective trial to examine panitumumab versus bevacizumab in colorectal cancer. Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the findings of the phase III PARADIGM study in patients with RAS wild-type (WT) metastatic colorectal cancer. The abstract entitled ‘Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment […]
Takayuki Yoshino, ASCO 2022: PARADIGM trial of panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with MCRC
Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!